Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and hiv-negative/non-transplant

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Bratton, Emily W ^a,e   El Husseini, Nada ^b,e   Chastain, Cody A ^c,e   Lee, Michael S ^d,e   Poole, Charles ^a,e   Stürmer, Til ^a,e   Juliano, Jonathan J ^d,e   Weber, David J ^a,d,e   Perfect, John R ^b,e  

^a IL   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYENE ANTIBIOTIC AGENT; PREDNISONE; RAPAMYCIN; VORICONAZOLE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CRYPTOCOCCOSIS; DISEASE SEVERITY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL PRESSURE; KIDNEY DYSFUNCTION; LIVER FAILURE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MORTALITY; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDY; TREND STUDY;

ADULT; AGED; CRYPTOCOCCOSIS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACRANIAL HYPERTENSION; MALE; MIDDLE AGED; TRANSPLANTS;

EID: 84865280800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043582     Document Type: Article

References (56)

1. Casadevall A, Perfect JR (1998) Cryptococcus neoformans. Washington, D.C.: ASM Press. viii, 541 p.
2. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50: 291-322.
3. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
4. Rust DM, Jameson G, (1998) The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice. Oncol Nurs Forum 25: 35-48.
5. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, et al. (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30: 710-718.
6. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, et al. (2010) Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 50: 338-344.
7. Jarvis JN, Dromer F, Harrison TS, Lortholary O, (2008) Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis 21: 596-603.
8. Pappas PG, Chetchotisakd P, Larsen RA, Manosuthi W, Morris MI, et al. (2009) A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 48: 1775-1783.
9. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, et al. (2008) High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 47: 123-130.
10. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, et al. (2008) Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 47: 1556-1561.
11. Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, et al. (2008) Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 46: 393-395.
12. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, et al. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363: 1764-1767.
13. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, et al. (2004) Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 18: 555-562.
14. French N, Gray K, Watera C, Nakiyingi J, Lugada E, et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16: 1031-1038.
15. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, et al. (1999) Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 179: 449-454.
16. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, et al. (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30Suppl 1: S5-14.
17. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, et al. (2003) The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 36: 789-794.
18. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, et al. (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337: 15-21.
19. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
20. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E, (2011) Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg Infect Dis 17: 193-199.
21. Galanis E, Hoang L, Kibsey P, Morshed M, Phillips P, (2009) Clinical presentation, diagnosis and management of Cryptococcus gattii cases: Lessons learned from British Columbia. Can J Infect Dis Med Microbiol 20: 23-28.
22. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, et al. (2008) Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 14: 755-762.
23. Ecevit IZ, Clancy CJ, Schmalfuss IM, Nguyen MH, (2006) The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis 42: 1443-1447.
24. Lui G, Lee N, Ip M, Choi KW, Tso YK, et al. (2006) Cryptococcosis in apparently immunocompetent patients. QJM 99: 143-151.
25. Nguyen MH, Husain S, Clancy CJ, Peacock JE, Hung CC, et al. (2010) Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect 61: 419-426.
26. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, et al. (2001) Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 33: 690-699.
27. Rozenbaum R, Goncalves AJ, (1994) Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 18: 369-380.
28. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, et al. (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 301: 126-131.
29. Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, et al. (1987) Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 317: 334-341.
30. Dromer F, Mathoulin S, Dupont B, Brugiere O, Letenneur L, (1996) Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin Infect Dis 22Suppl 2: S154-160.
31. Byrnes EJ, 3rd, Li W, Lewit Y, Perfect JR, Carter DA, et al (2009) First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One 4: e5851.
32. Lin X, Heitman J, (2006) The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol 60: 69-105.
33. Singh N, Perfect JR, (2007) Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 7: 395-401.
34. Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, et al. (2007) Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 195: 756-764.
35. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D, (2000) Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 44: 2373-2381.
36. Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS, (2003) Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 51: 313-316.
37. Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, et al. (2008) Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 52: 735-738.
38. Del Poeta M, Cruz MC, Cardenas ME, Perfect JR, Heitman J, (2000) Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 44: 739-746.
39. Person AK, Kontoyiannis DP, Alexander BD, (2010) Fungal infections in transplant and oncology patients. Infect Dis Clin North Am 24: 439-459.
40. Lawn SD, Torok ME, Wood R, (2011) Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 24: 34-42.
41. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, (2007) Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 4: e21.
42. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, et al. (2006) Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20: 2183-2191.
43. Singh N, Dromer F, Perfect JR, Lortholary O, (2008) Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 47: 1321-1327.
44. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, et al. (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50: 1101-1111.
45. Singh N, Lortholary O, Dromer F, Alexander BD, Gupta KL, et al. (2008) Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation 86: 647-651.
46. Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, et al. (2009) Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 49: 1721-1728.
47. Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, et al. (2002) Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis 4: 183-188.
48. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R, (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19: 2141-2148.
49. Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, et al. (2009) Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 49: 702-709.
50. Loyse A, Wilson D, Meintjes G, Jarvis JN, Bicanic T, et al. (2012) Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 54: 121-128.
51. Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, et al. (2009) Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 51: 130-134.
52. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, et al. (2005) Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19: 1043-1049.
53. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, et al. (2005) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19: 399-406.
54. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S, (2007) Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr 45: 595-596.
55. Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, et al. (2010) Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 51: 225-232.
56. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, et al. (1997) Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11: 1463-1471.